Latest news with #DIAGNOS
Globe and Mail
2 days ago
- Business
- Globe and Mail
DIAGNOS Welcomes Founder of National Vision Associates, Ed Weiner, to its Advisory Board for the United States
BROSSARD, Quebec, June 10, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. ('DIAGNOS' or the 'Corporation') (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues using advanced technology based on Artificial Intelligence (AI), is thrilled to announce that Mr. Ed Weiner has joined the Corporation's Advisory Board. Mr. Weiner will team up with Dr. Tomas J. Philipson, former vice chairman and acting chairman of the White House Council of Economic Advisers, to provide valuable insights to DIAGNOS about the US optical market. Mr. Weiner is a seasoned entrepreneur and has been a leader in the optical industry for decades. He was the first to introduce Ralph Lauren Eyewear. He also partnered with Walmart to open 400 optical locations within Walmart's chain of stores. Mr. Weiner was also chairman and founder of National Vision Associates, one of the largest optical retailers in the USA. 'We are honored to welcome Ed to our Advisory Board,' said André Larente, President and CEO of DIAGNOS. 'In our opinion, his deep knowledge of the US optical market will contribute to bring DIAGNOS as one of the main AI driven healthcare solutions among opticians and optometrists across the US.' Mr. Larente added, 'DIAGNOS has built an AI platform to analyze retina images, these images are taken by thousands of optometrists worldwide. According to recent VisionWatch data, the US saw approximately 111 million routine eye exams and 60 million medical eye exams in 2020. DIAGNOS, along with its partners can address this growing market'. DIAGNOS recently opened its US office in south Florida to support its US prospects and clients. About DIAGNOS DIAGNOS is a publicly traded Canadian corporation dedicated to early detection of critical eye-related health problems. By leveraging Artificial Intelligence, DIAGNOS aims to provide more information to healthcare clinicians to enhance diagnostic accuracy, streamline workflows, and improve patient outcomes on a global scale. Additional information is available at and Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Yahoo
23-05-2025
- Business
- Yahoo
DIAGNOS Announces the Engagement of Allele Capital Partners
BROSSARD, Quebec, May 23, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. ('DIAGNOS' or the 'Corporation') (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues using advanced technology based on Artificial Intelligence (AI), announces the engagement of Allele Capital Partners, LLC ('Allele') to provide capital markets advisory and social media services to the Corporation. As per the agreement signed between Allele and DIAGNOS, Allele is entitled to a monthly compensation of US$7,500, payable in advance in cash, for the period of May 22, 2025 to August 22, 2025 (the 'Trial Period'). During the Trial Period, DIAGNOS may terminate the agreement at its sole discretion with thirty (30) business days advanced written notice to Allele. Upon expiry of the Trial Period, the agreement shall renew, upon written confirmation from DIAGNOS, for an additional nine (9) months at the same monthly compensation fee of US$7,500. At its sole discretion, Allele may terminate the agreement at any time during the term. The compensation will be paid using the liquidities of the Corporation. Headquartered in Southeast Florida, USA, Allele provides capital markets advisory and merchant banking services to life science companies. As part of the services to be rendered to the Corporation, Allele will assist DIAGNOS in refining and strengthening its business strategy in order to optimize milestones, capital needs and capital markets objectives with the ultimate goal of maximizing shareholder value. Allele is acting at arm's length to the Corporation. As of the date of this announcement, Allele, together with any of its principals, do not have any interest, directly or indirectly, in the securities of the Corporation. The engagement of Allele is subject to the acceptance of the TSX Venture Exchange. About DIAGNOSDIAGNOS is a publicly traded Canadian corporation dedicated to early detection of critical eye-related health problems. By leveraging Artificial Intelligence, DIAGNOS aims to provide more information to healthcare clinicians to enhance diagnostic accuracy, streamline workflows, and improve patient outcomes on a global scale. Additional information is available at and This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. CONTACT: For further information, please contact: Mr. André Larente, President DIAGNOS Inc. Tel: 450-678-8882 ext. 224 alarente@ while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
20-05-2025
- Business
- Yahoo
DIAGNOS Announces Amendment to Convertible Debentures
BROSSARD, Quebec, May 20, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. ('DIAGNOS' or the 'Corporation') (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues using advanced technology based on Artificial Intelligence (AI), announces that it intends to extend the maturity date for $300,000 unsecured convertible debentures (each a 'Debenture') issued as part of a private placement of units initially announced on May 18, 2023. The maturity date, initially set for May 18, 2025, is being extended to May 18, 2026 (the 'Amendment'). All other provisions of the Debentures will remain unchanged and fully in effect during the extension period. One insider of the Corporation is the beneficial owner of two (2) Debentures for an aggregate nominal value of $100,000. Assuming the (i) conversion of the Debentures and (ii) exercise of all outstanding securities, the insider would own 3,446,056 common shares of the Corporation representing 3.35% of the total issued common shares, on a partially diluted basis. The insider is considered a 'related party' of the Corporation within the meaning of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions ('MI 61-101'). The Amendment is exempt from the valuation requirement and the minority approval requirement prescribed in MI 61-101, based on sections 5.5(a) and 5.7(1)(a), as the fair market value of the related party participation in the amendment to convertible debentures does not exceed 25% of the Corporation's current market capitalization. The board of directors of the Corporation has reviewed and approved the Amendment to ensure that it was in the best interest of DIAGNOS and its shareholders. The Amendment remains subject to the TSX Venture Exchange acceptance as well as execution of formal documentation. All monies quoted in this press release shall be stated and paid in lawful money of Canada. About DIAGNOSDIAGNOS is a publicly traded Canadian corporation dedicated to early detection of critical eye-related health problems. By leveraging Artificial Intelligence, DIAGNOS aims to provide more information to healthcare clinicians to enhance diagnostic accuracy, streamline workflows, and improve patient outcomes on a global scale. Additional information is available at and This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. CONTACT: For further information, please contact: Mr. André Larente, President DIAGNOS Inc. Tel: 450-678-8882 ext. 224 alarente@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
09-04-2025
- Business
- Yahoo
DIAGNOS Provides Update on its Health Canada Medical Device Licence Application
BROSSARD, Quebec, April 09, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. ('DIAGNOS' or the 'Corporation') (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of certain ophthalmic health issues using advanced technology based on Artificial Intelligence (AI), provides an update on the progress of its Medical device license application for CARA System, submitted to Health Canada in early September 2024. Following the submission of its application in early September, DIAGNOS has engaged in ongoing communication with Health Canada, providing timely responses to all regulatory requests. After more than 11 proactive inquiries regarding the application's status, we are pleased to announce that Health Canada has confirmed that the application is now under 'active processing', having progressed from a previous backlog. "We remain steadfast to complying with all regulatory requirements and ensuring that Health Canada has all the necessary information to support the review of our CARA System application," said André Larente, CEO of Diagnos Inc. "We appreciate the continued collaboration with Health Canada and are optimistic about the future progress of our application." Diagnos Inc. is dedicated to advancing its mission of providing cutting-edge medical diagnostic solutions, and the CARA System is a key part of the company's growth strategy. About DIAGNOSDIAGNOS is a publicly traded Canadian corporation dedicated to early detection of critical eye-related health problems. By leveraging Artificial Intelligence, DIAGNOS aims to provide more information to healthcare clinicians to enhance diagnostic accuracy, streamline workflows, and improve patient outcomes on a global scale. Additional information is available at and This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. CONTACT: For further information, please contact: Mr. André Larente, President DIAGNOS Inc. Tel: 450-678-8882 ext. 224 alarente@
Yahoo
28-01-2025
- Business
- Yahoo
DIAGNOS to Present at The Microcap Conference 2025
BROSSARD, Quebec, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. ('DIAGNOS' or the 'Corporation') (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), is pleased to announce its participation in The Microcap Conference 2025, the premier event for growth-focused companies and investors. The conference will take place January 28-30, 2025, at the Borgata Hotel Spa & Casino in Atlantic City, NJ. Details of the presentation: Event: The Microcap Conference Date and Time: January 29, 2025, at 4:30 p.m., ET Location: Borgata Hotel Casino & Spa, Studio C, Atlantic City, NJ Presenter: André Larente, Chief Executive Officer DIAGNOS will engage in one-on-one meetings with institutional and individual investors to discuss the Company's recent developments, growth strategy, and investment opportunities. This event provides a unique platform to highlight DIAGNOS' AI technology and its vision for disrupting medical detection landscape. 'Our Investor Relations strategy is to connect with U.S. investors who recognize the importance of innovation in healthcare. This event provides an excellent opportunity to increase awareness with family offices, wealth management advisors, and high-net-worth individuals. With expected deployments with customers, as well as a partnership with the largest eyecare company in the world that validated our technology and will commercialize to its customer base, 2025 could be a milestone year for DIAGNOS,' said André Larente, CEO of DIAGNOS. To register for the conference or one-on-one meeting, visit About The Microcap Conference 2025 The Microcap Conference is the largest independent microcap event in the U.S., bringing together top-tier investors and executives from microcap companies. The event offers a platform for companies to showcase their value propositions through presentations, one-on-one meetings, and networking opportunity. The 2025 event will feature: Keynote Speakers: Renowned industry figures, including Jon Ledecky, Co-Owner of the New York Islanders, who will engage in a fireside chat with CNBC's Bob Pisani, and Tom Gardner, CEO of Motley Fool, who will share insights on investing, market trends, and entrepreneurial success. Expert Panels and Presentations: Financial commentators Ron Insana (CNBC) and Charlie Gasparino (FOX Business) will cover critical topics for the US equity markets, from capital formation to regulatory updates and market trends. Entertainment Headliner: A special performance by Tom Papa, celebrated comedian and host of Netflix specials, ensuring a memorable evening for attendees. Hosted by DealFlow Events, The Microcap Conference is renowned for its blend of high-quality content, engaging networking, and exceptional entertainment. About DIAGNOSDIAGNOS is a publicly traded Canadian corporation dedicated to early detection of critical health problems based on its FLAIRE Artificial Intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications such as CARA (Computer Assisted Retina Analysis). CARA's image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients. Additional information is available at and This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. CONTACT: For further information, please contact: Mr. André Larente, President DIAGNOS Inc. Tel: 450-678-8882 ext. 224 alarente@ in to access your portfolio
